| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, Androgen | 38 | 2026 | 86 | 8.610 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 17 | 2026 | 46 | 6.540 |
Why?
|
| Prostatic Neoplasms | 31 | 2025 | 493 | 6.520 |
Why?
|
| Gene Expression Regulation, Neoplastic | 25 | 2026 | 583 | 4.020 |
Why?
|
| Histone Demethylases | 9 | 2024 | 28 | 2.880 |
Why?
|
| Cell Line, Tumor | 40 | 2026 | 1565 | 2.650 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 7 | 2024 | 21 | 1.980 |
Why?
|
| Retinoblastoma Protein | 5 | 2025 | 45 | 1.880 |
Why?
|
| Transcription, Genetic | 11 | 2024 | 907 | 1.240 |
Why?
|
| Androgens | 13 | 2025 | 66 | 1.240 |
Why?
|
| Testosterone | 4 | 2025 | 128 | 1.190 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2025 | 64 | 1.160 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2017 | 217 | 1.090 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 3 | 2017 | 9 | 0.970 |
Why?
|
| Histones | 5 | 2023 | 494 | 0.960 |
Why?
|
| Male | 46 | 2026 | 31047 | 0.950 |
Why?
|
| Protein Binding | 11 | 2020 | 1640 | 0.900 |
Why?
|
| Chromatin | 9 | 2024 | 641 | 0.890 |
Why?
|
| E2F1 Transcription Factor | 2 | 2022 | 18 | 0.860 |
Why?
|
| Transcription Factor AP-1 | 2 | 2024 | 46 | 0.850 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2024 | 8 | 0.850 |
Why?
|
| DNA-Binding Proteins | 6 | 2020 | 1225 | 0.840 |
Why?
|
| Signal Transduction | 15 | 2025 | 3153 | 0.830 |
Why?
|
| Mice | 23 | 2026 | 11119 | 0.790 |
Why?
|
| Serine Endopeptidases | 3 | 2025 | 121 | 0.790 |
Why?
|
| Androstenes | 5 | 2016 | 9 | 0.790 |
Why?
|
| Prostatic Hyperplasia | 1 | 2023 | 35 | 0.780 |
Why?
|
| Transcription Factors | 6 | 2023 | 1556 | 0.780 |
Why?
|
| Cell Lineage | 1 | 2024 | 282 | 0.760 |
Why?
|
| SOX9 Transcription Factor | 3 | 2024 | 13 | 0.720 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2022 | 9 | 0.720 |
Why?
|
| Mice, SCID | 9 | 2025 | 518 | 0.680 |
Why?
|
| Humans | 48 | 2026 | 65140 | 0.660 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2022 | 78 | 0.660 |
Why?
|
| Animals | 27 | 2026 | 21345 | 0.640 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 26 | 0.630 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 285 | 0.630 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2026 | 203 | 0.610 |
Why?
|
| Cyclic GMP | 1 | 2019 | 33 | 0.580 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2021 | 440 | 0.570 |
Why?
|
| Ketoconazole | 2 | 2017 | 11 | 0.540 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2017 | 5 | 0.510 |
Why?
|
| Proto-Oncogene Proteins c-jun | 4 | 2024 | 34 | 0.500 |
Why?
|
| Cell Proliferation | 11 | 2019 | 1038 | 0.500 |
Why?
|
| Codon, Nonsense | 1 | 2017 | 62 | 0.490 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 364 | 0.480 |
Why?
|
| Enhancer Elements, Genetic | 4 | 2024 | 119 | 0.480 |
Why?
|
| Androstenols | 3 | 2014 | 3 | 0.470 |
Why?
|
| Prostate | 4 | 2020 | 122 | 0.430 |
Why?
|
| Progesterone | 2 | 2014 | 165 | 0.430 |
Why?
|
| Transcriptional Activation | 5 | 2022 | 197 | 0.420 |
Why?
|
| Trans-Activators | 2 | 2013 | 321 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 464 | 0.400 |
Why?
|
| Androgen Receptor Antagonists | 4 | 2020 | 8 | 0.400 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2023 | 37 | 0.400 |
Why?
|
| Lysine | 2 | 2023 | 94 | 0.390 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2024 | 84 | 0.390 |
Why?
|
| Transfection | 5 | 2021 | 700 | 0.370 |
Why?
|
| Guanylate Cyclase | 1 | 2011 | 11 | 0.360 |
Why?
|
| Pregnenolone | 1 | 2011 | 4 | 0.350 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 12 | 0.350 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1222 | 0.340 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2011 | 151 | 0.330 |
Why?
|
| Carcinoma | 1 | 2011 | 130 | 0.320 |
Why?
|
| Cytoplasm | 1 | 2011 | 283 | 0.320 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2018 | 128 | 0.320 |
Why?
|
| Transcriptional Regulator ERG | 3 | 2025 | 9 | 0.300 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 367 | 0.300 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2011 | 318 | 0.300 |
Why?
|
| Protein Transport | 4 | 2019 | 405 | 0.300 |
Why?
|
| Disease Progression | 4 | 2025 | 1220 | 0.290 |
Why?
|
| Alternative Splicing | 2 | 2024 | 138 | 0.290 |
Why?
|
| DNA Replication | 3 | 2025 | 247 | 0.280 |
Why?
|
| ErbB Receptors | 1 | 2009 | 127 | 0.280 |
Why?
|
| Orchiectomy | 3 | 2012 | 40 | 0.260 |
Why?
|
| RNA Interference | 3 | 2019 | 643 | 0.250 |
Why?
|
| Protein Phosphatase 1 | 2 | 2017 | 19 | 0.250 |
Why?
|
| Cellular Reprogramming | 2 | 2024 | 41 | 0.240 |
Why?
|
| Soluble Guanylyl Cyclase | 2 | 2019 | 4 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2026 | 104 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2025 | 215 | 0.230 |
Why?
|
| Proteolysis | 4 | 2016 | 154 | 0.230 |
Why?
|
| Protein Isoforms | 2 | 2024 | 201 | 0.220 |
Why?
|
| Single-Cell Analysis | 1 | 2026 | 116 | 0.220 |
Why?
|
| Nitric Oxide | 2 | 2019 | 164 | 0.220 |
Why?
|
| Methyltransferases | 2 | 2023 | 67 | 0.220 |
Why?
|
| Binding Sites | 2 | 2019 | 921 | 0.220 |
Why?
|
| Physical Conditioning, Animal | 1 | 2025 | 47 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 3 | 2013 | 287 | 0.210 |
Why?
|
| Cell Plasticity | 1 | 2024 | 24 | 0.210 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2022 | 17 | 0.200 |
Why?
|
| Neoplastic Processes | 1 | 2023 | 3 | 0.200 |
Why?
|
| Demethylation | 1 | 2023 | 4 | 0.200 |
Why?
|
| Gene Knockout Techniques | 2 | 2022 | 97 | 0.200 |
Why?
|
| Neoplasm Metastasis | 1 | 2024 | 222 | 0.200 |
Why?
|
| Histocompatibility Antigens | 1 | 2023 | 107 | 0.200 |
Why?
|
| Heterografts | 2 | 2020 | 66 | 0.190 |
Why?
|
| Bone Neoplasms | 1 | 2024 | 121 | 0.190 |
Why?
|
| Methylation | 2 | 2014 | 130 | 0.190 |
Why?
|
| COS Cells | 4 | 2017 | 180 | 0.190 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 407 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 542 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2023 | 113 | 0.180 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 178 | 0.180 |
Why?
|
| Drug Discovery | 2 | 2013 | 96 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2022 | 12 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 18 | 0.180 |
Why?
|
| DNA Repair | 2 | 2022 | 262 | 0.180 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2022 | 226 | 0.170 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2020 | 5 | 0.160 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2020 | 21 | 0.160 |
Why?
|
| Enzyme Activation | 2 | 2013 | 391 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 402 | 0.160 |
Why?
|
| Dihydrotestosterone | 2 | 2013 | 21 | 0.160 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2020 | 36 | 0.160 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 19 | 0.160 |
Why?
|
| Dutasteride | 2 | 2017 | 4 | 0.160 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2020 | 88 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 68 | 0.150 |
Why?
|
| DNA Damage | 1 | 2022 | 297 | 0.150 |
Why?
|
| Base Sequence | 2 | 2014 | 1332 | 0.150 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2019 | 3 | 0.150 |
Why?
|
| Leuprolide | 2 | 2016 | 18 | 0.150 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2020 | 268 | 0.150 |
Why?
|
| Sulfonamides | 2 | 2026 | 136 | 0.140 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2019 | 251 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2021 | 394 | 0.140 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 790 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2020 | 302 | 0.140 |
Why?
|
| Androgen Antagonists | 2 | 2018 | 32 | 0.140 |
Why?
|
| Recurrence | 1 | 2019 | 657 | 0.130 |
Why?
|
| Naphthoquinones | 1 | 2017 | 4 | 0.130 |
Why?
|
| Zebrafish | 1 | 2021 | 374 | 0.130 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2017 | 9 | 0.130 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 167 | 0.130 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2017 | 12 | 0.130 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2017 | 11 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 730 | 0.130 |
Why?
|
| Imidazoles | 1 | 2017 | 82 | 0.120 |
Why?
|
| Cell Survival | 3 | 2017 | 587 | 0.120 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 135 | 0.120 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 52 | 0.120 |
Why?
|
| Phenylthiohydantoin | 3 | 2026 | 4 | 0.120 |
Why?
|
| RNA, Small Interfering | 3 | 2019 | 981 | 0.120 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2017 | 182 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 687 | 0.120 |
Why?
|
| Benzamides | 3 | 2026 | 69 | 0.110 |
Why?
|
| Nitriles | 3 | 2026 | 82 | 0.110 |
Why?
|
| Ubiquitination | 1 | 2016 | 117 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 86 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2015 | 38 | 0.110 |
Why?
|
| Mutation | 4 | 2020 | 2661 | 0.110 |
Why?
|
| Phosphorylation | 5 | 2018 | 962 | 0.110 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2015 | 48 | 0.110 |
Why?
|
| Consensus Sequence | 1 | 2014 | 30 | 0.110 |
Why?
|
| Androstadienes | 1 | 2014 | 43 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2014 | 105 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2014 | 56 | 0.100 |
Why?
|
| Phosphotyrosine | 1 | 2013 | 25 | 0.100 |
Why?
|
| Transcriptome | 2 | 2015 | 399 | 0.100 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2012 | 17 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 61 | 0.100 |
Why?
|
| Pyridones | 1 | 2013 | 42 | 0.100 |
Why?
|
| Down-Regulation | 2 | 2011 | 324 | 0.100 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 33 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 32 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 40 | 0.090 |
Why?
|
| Response Elements | 1 | 2011 | 44 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 297 | 0.090 |
Why?
|
| Androstenedione | 1 | 2011 | 9 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 197 | 0.090 |
Why?
|
| Dehydroepiandrosterone | 1 | 2011 | 14 | 0.090 |
Why?
|
| Luciferases | 1 | 2011 | 107 | 0.090 |
Why?
|
| Indomethacin | 1 | 2011 | 23 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 2 | 2014 | 426 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 152 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2011 | 257 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2025 | 88 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2011 | 374 | 0.080 |
Why?
|
| Computational Biology | 1 | 2012 | 367 | 0.080 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1290 | 0.070 |
Why?
|
| Epidermal Growth Factor | 1 | 2009 | 49 | 0.070 |
Why?
|
| Time Factors | 1 | 2017 | 3762 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2017 | 5792 | 0.070 |
Why?
|
| DNA Primers | 1 | 2009 | 301 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2011 | 1574 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 17 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2007 | 64 | 0.060 |
Why?
|
| Amino Acid Motifs | 2 | 2018 | 156 | 0.060 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2026 | 23 | 0.060 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Mice, Inbred ICR | 2 | 2018 | 33 | 0.060 |
Why?
|
| RNA Polymerase II | 1 | 2006 | 86 | 0.060 |
Why?
|
| Mitochondrial Dynamics | 1 | 2025 | 13 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2016 | 286 | 0.060 |
Why?
|
| Ribonucleoproteins | 1 | 2006 | 116 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2020 | 1589 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase 9 | 2 | 2017 | 8 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2025 | 75 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2018 | 616 | 0.050 |
Why?
|
| CDC2 Protein Kinase | 2 | 2017 | 38 | 0.050 |
Why?
|
| Castration | 2 | 2014 | 43 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2006 | 428 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2014 | 202 | 0.050 |
Why?
|
| HeLa Cells | 2 | 2016 | 541 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2013 | 1162 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 39 | 0.030 |
Why?
|
| Adenine | 1 | 2018 | 48 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 676 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 73 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2022 | 369 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2018 | 129 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2018 | 88 | 0.030 |
Why?
|
| Antibodies | 1 | 2018 | 187 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2018 | 145 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 2293 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 180 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 142 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2017 | 59 | 0.030 |
Why?
|
| Transcription Factor 4 | 1 | 2016 | 3 | 0.030 |
Why?
|
| Pyrans | 1 | 2016 | 2 | 0.030 |
Why?
|
| Pyrazines | 1 | 2016 | 35 | 0.030 |
Why?
|
| Spiro Compounds | 1 | 2016 | 12 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 33 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 41 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2016 | 84 | 0.030 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2015 | 3 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2016 | 364 | 0.030 |
Why?
|
| Pyridines | 1 | 2016 | 119 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 611 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 146 | 0.020 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2013 | 17 | 0.020 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2013 | 8 | 0.020 |
Why?
|
| Peptide Library | 1 | 2013 | 33 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 52 | 0.020 |
Why?
|
| Receptor, Insulin | 1 | 2013 | 52 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 117 | 0.020 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2012 | 19 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 233 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2014 | 198 | 0.020 |
Why?
|
| Structural Homology, Protein | 1 | 2012 | 22 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 61 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 137 | 0.020 |
Why?
|
| Protein Kinase C-alpha | 1 | 2011 | 17 | 0.020 |
Why?
|
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2011 | 12 | 0.020 |
Why?
|
| G1 Phase | 1 | 2012 | 58 | 0.020 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 47 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 260 | 0.020 |
Why?
|
| S Phase | 1 | 2012 | 79 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2011 | 46 | 0.020 |
Why?
|
| Serine | 1 | 2012 | 90 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 663 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 238 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 132 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 190 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 433 | 0.020 |
Why?
|
| Female | 1 | 2011 | 34018 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2012 | 630 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1098 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 2157 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 643 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1698 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 1192 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2011 | 718 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2620 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2006 | 71 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2005 | 3 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2006 | 55 | 0.010 |
Why?
|
| Antigens | 1 | 2006 | 145 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 5614 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2006 | 570 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 14965 | 0.010 |
Why?
|
| Middle Aged | 1 | 2014 | 18273 | 0.010 |
Why?
|